Investing over 0.4 billion, Qiming Venture Capital enters Zhengzhou Tiamaes Technology. Is the "shell buying craze" restarting?

① After this Trade is completed, the controlling Shareholder of Zhengzhou Tiamaes Technology will change to Qiming Fund, and the actual controller of the listed company will change to Kuang Ziping. The latter is the founding managing partner of Qiming Venture Capital. ② People from the Venture Capital Institutions indicate that Qiming Venture Capital's entry into Zhengzhou Tiamaes Technology this time may ultimately aim to realize investment exit by injecting its Assets into the listed company. ③ A wave of "shell buying" by Venture Capital Institutions occurred in the A-share market in 2019.

cls.cnJan 7 17:58

Zhengzhou Tiamaes Technology's "change of ownership" plan has emerged: Trade sets "different pricing for the same shares" with well-known VC participating in the integration.

① The well-known VC Qiming Venture Capital founder Kuang Ziping is about to become the actual controller of Zhengzhou Tiamaes Technology; ② This Trade adopts differentiated pricing, and industry insiders indicate that differentiated pricing helps provide more negotiation space, which can facilitate the acquisition and achieve a fair Trade.

cls.cnJan 7 15:46

Local state-owned assets took over the equity of private enterprises, the 19% equity change of Xiamen Jinzu was approved, and last year many Jinzu companies experienced changes in their equity.

① This morning, the official website of the National Financial Regulatory Administration announced that it agreed to allow Xiamen Xiangyu Asset Management Operation Co., Ltd. to acquire 19% of the shares in Xiamen Financial Leasing Co., Ltd. held by Peking Tongyuan Pharmaceutical Technology Co., Ltd. ② From the equity structure perspective, this is a typical case of local state-owned assets taking over the equity of a private enterprise in the financial leasing industry.

cls.cnJan 3 16:32

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Policy stimulus for 3C and home appliance demand release. Will the multiplier effect of the "trade-in" policy continue in 2025? | Year-end review.

In 2024, the implementation of the "national subsidy" policy for the exchange of old for new will effectively stimulate the demand for home appliances and Consumer Electronics. Market analysis suggests that related subsidies for the exchange of old for new are expected to continue next year, with mobile phones and more home improvement categories likely included, while the future policy-driven effects still remain to be observed.

cls.cnDec 29, 2024 23:17

The 2024 yellow-feathered chicken market is "full of ups and downs," where is the "dawn" of corporate profits in 2025? | Year-end summary.

1. Driven by cost reduction and efficiency improvement, the yellow-feathered chicken enterprises show strong performance in 2024, with Wens Foodstuff Group, Jiangsu Lihua Animal Husbandry, and Hunan Xiang Jia husbandry achieving net income growth of 241.47%, 507.71%, and 259.71% year-on-year in the first three quarters; 2. Looking ahead to 2025, some industry insiders believe that with the support of dual engines of cost reduction and consumer boost, the enterprises' profitability is expected to continue to be maintained.

cls.cnDec 29, 2024 18:05